Strategic Initiative

Slingshot members are tracking this corporate initiative:

Cardiome and Allergan Announce XYDALBA (Dalbavancin) Licensing Agreement in International Markets

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details Cardiome has signed an exclusive license agreement with an affiliate of Allergan plc that will result in the Cardiome Group commercializing XYDALBA (Dalbavancin) in France, the U.K., Germany, Belgium, Nordic nations, certain other European nations (not already partnered), various Middle Eastern nations and Canada. Cardiome will provide Allergan with a staggered upfront payment totalling US$13 million and will provide Allergan additional milestone payments and royalties based upon commercial achievements and sales of XYDALBA. Additional terms of the agreement were not disclosed.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
May 05, 2016
Projected Implementation:
Q2, 2016
Relevance Tracked Until:
Q4, 2016
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Xydalba, Dalbavancin, Licensing Agreement